Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Connect Biopharma Holdings (CNTB) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Connect Biopharma Holdings (CNTB) over the last 2 years, with Q3 2025 value amounting to 106887.5%.

  • Connect Biopharma Holdings' EBITDA Margin fell 1058779800.0% to 106887.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 6558.01%, marking a year-over-year change of. This contributed to the annual value of 62.56% for FY2024, which is N/A changed from last year.
  • Connect Biopharma Holdings' EBITDA Margin amounted to 106887.5% in Q3 2025, which was down 1058779800.0% from 26393.75% recorded in Q2 2025.
  • Over the past 5 years, Connect Biopharma Holdings' EBITDA Margin peaked at 1009.52% during Q3 2024, and registered a low of 106887.5% during Q3 2025.